Back to Search
Journal ArticleOpen Access

The challenges of introducing routine G6PD testing into radical cure: a workshop report

Author Affiliations
Charles Darwin University, Menzies School of Health Research, Program for Appropriate Technology in Health, Research Institute for Tropical Medicine, ...
Published InMalaria Journal
Year2015
Citations80

Abstract

The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recommended routine testing of G6PD status prior to primaquine radical cure whenever possible. A workshop was held in the Philippines in early 2015 to discuss key challenges and knowledge gaps that hinder the introduction of routine G6PD testing. Two point-of-care (PoC) test formats for the measurement of G6PD activity are currently available: qualitative tests comparable to malaria…
View at Publisher

BORR does not host full-text PDFs. The button above takes you to the original publisher.